Clinical trial
Isotretinoin, Interferon Alpha-2b, and Paclitaxel in Stage IV, Recurrent, or…
NCT00138151 · University of Medicine and Dentistry of New Jersey, Other · Terminated
Key facts
| NCT number | NCT00138151 |
|---|---|
| Title | Isotretinoin, Interferon Alpha-2b, and Paclitaxel in Stage IV, Recurrent, or Persistent Cervical Cancer |
| Official title | A Phase II Trial of Chemosensitization With Paclitaxel, 13-cis Retinoic Acid and Interferon Alpha-2b in Advanced Uterine Cervical Carcinoma |
| Lead sponsor | University of Medicine and Dentistry of New Jersey, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Cervical Cancer |
| Intervention type | Biological, Drug |
| Interventions | recombinant interferon alpha-2b, isotretinoin, paclitaxel |
| Enrollment | 33 |
| Start date | Mar 1, 2001 |
| Primary completion | Nov 1, 2010 |
| Completion | Nov 1, 2010 |
| First posted | Aug 30, 2005 |
| Last update posted | Nov 20, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: